ProMIS Neurosciences Announces CDN$3 Million Best-Efforts Private Placement /NOT FOR DISTRIBUTION TO US NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES/ TORONTO, ON – July 20, 2017 – ProMIS Neurosciences Inc. (“ProMIS” or the “Company”) (TSX:PMN; OTCPK:ARFX.F; DB:23J) today…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Presents at AAIC 2017 Data from Alzheimer’s Disease Program Company Focused on Development of Antibodies that Selectively Target Toxic, Prion-Like Forms of Amyloid beta ProMIS Issues White Paper from…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation Updated corporate overview available on ProMIS website TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 10, 2017 –…
ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN FOR IMMEDIATE RELEASE ProMIS™ Neurosciences’ Sponsored Research Agreement with University of British Columbia Receives Matching Grant from Canadian Institutes of Health Research TORONTO, Ontario and CAMBRIDGE, Massachusetts – July 6, 2017 – ProMIS Neurosciences,…
ProMIS Neurosciences, Inc. NEWS RELEASE TSX: PMN/FOR IMMEDIATE RELEASE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC): 16-20 JULY, 2017 LONDON, ENGLAND ProMIS Neurosciences to Present Preclinical Data from Alzheimer’s Disease Program at AAIC 2017 Chief Development Officer Dr. Johanne Kaplan to…
ProMIS™ Neurosciences, Inc. NEWS RELEASE TSX: PMN FOR IMMEDIATE RELEASE ProMIS™ Neurosciences Appoints William C. Mobley to Scientific Advisory Board TORONTO, Ontario and CAMBRIDGE, Massachusetts – June 6, 2017 – ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development…